Stay updated on Risankizumab in PsA Patients: Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.

Latest updates to the Risankizumab in PsA Patients: Clinical Trial page
- Check4 days agoChange DetectedThe page no longer displays the AbbVie sponsor attribution and the auxiliary sections 'Related Info' and 'Helpful Links Provided by', altering how users access sponsor details and related resources for this study.SummaryDifference0.0%

- Check11 days agoChange DetectedThe page now displays a new revision tag, replacing the previous v3.5.3 with v3.5.4. This indicates a software release or UI/template update to the page rather than changes to the study details or content.SummaryDifference0.0%

- Check19 days agoChange DetectedTwo trial-site entries were updated to use correctly spelled city names with diacritics (Malmö and Taoyuan City) instead of the previously listed forms. The update standardizes geographic identifiers on the study's site list while preserving the country and postal code information.SummaryDifference0.0%

- Check27 days agoChange DetectedKEEPSAKE page revision tag updated from v3.5.2 to v3.5.3, indicating a newer version of the page's documentation. This update is metadata-level and does not alter the trial details or substantive information presented.SummaryDifference0.0%

- Check34 days agoChange DetectedThe facility location name in Latvia was changed from “Ādaži” to “Adazi” while retaining the same address/city details.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Risankizumab in PsA Patients: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.